ACQUISITION (Details) $ / shares in Units, $ in Thousands |
1 Months Ended |
|---|---|
|
Oct. 31, 2023
USD ($)
Right
$ / shares
| |
| ACQUISITION | |
| Transaction costs | $ | $ 2,645 |
| Zynerba Acquisition | |
| ACQUISITION | |
| Cash consideration per Common Stock | $ / shares | $ 1.1059 |
| Aggregate consideration | $ | $ 60,000 |
| Number of contingent value right per Common Stock | Right | 1 |
| Contingent consideration per Common Stock | $ / shares | $ 2.5444 |
| X | ||||||||||
- Definition The contingent consideration per Common Stock, per the Tender Offer. No definition available.
|
| X | ||||||||||
- Definition Represents the number of contingent value right per Common Stock, for each holder of Common Stock upon the closing of the Tender Offer. No definition available.
|
| X | ||||||||||
- Definition The cash amount paid per Common Stock, per the Tender Offer. No definition available.
|
| X | ||||||||||
- Definition Amount of transaction cost incurred as part of consideration transferred in asset acquisition. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|